DaVita Inc. DVA
183.50 USD +4.22 (+2.35%)
At closeNov 11, 2026, 4:00 PM EST
183.55 +0.05 +0.03%
After hours · Nov 11, 4:00 PM ET
177.32 Day range 183.50
101.00 52-week range 247.49
- YTD
- +61.52%
- 1 year
- +50.08%
News
zacks.com DaVita HealthCare (DVA) is a Top-Ranked Value Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA). Such investors are advised to contact…
seekingalpha.com DaVita Inc. (DVA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript DaVita Inc. (DVA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
marketbeat.com DaVita Sees Growth and Drug Savings Offsetting 2027 Reimbursement Pressure DaVita NYSE: DVA expects stronger dialysis treatment growth and pharmaceutical cost savings to help offset reimbursement pressures in 2027, though Chief Financial Officer Joel Ackerman said changes…
globenewswire.com Lowey Dannenberg, P.C. is Investigating DaVita Inc. (NYSE: DVA) for Potential Violations of the Federal Securities Laws NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating DaVita Inc. (NYSE: DVA) (“DaVita” or the…
seekingalpha.com DaVita Inc. (DVA) Presents at 2026 UBS Global Healthcare Conference Transcript DaVita Inc. (DVA) Presents at 2026 UBS Global Healthcare Conference Transcript
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. ("DaVita" or the "Company") (NYSE: DVA). Such investors are advised to contact…
zacks.com Investors Heavily Search DaVita Inc. (DVA): Here is What You Need to Know DaVita HealthCare (DVA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
businesswire.com Did You Lose Money on DaVita Inc. Stock? The Law Offices of Howard G. BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on DaVita Inc. ("DaVita" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA). Such investors are advised to contact…
prnewswire.com DaVita Inc. to Participate in Upcoming Investor Conferences DENVER, Nov. 3, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) today announced that its Chief Financial Officer, Joel Ackerman, and its Group Vice President of Investor Relations, Nic Eliason, will…
businesswire.com Lost Money on DaVita Inc. Shares? The Law Offices of Frank R. LOS ANGELES--(BUSINESS WIRE)--DaVita Inc. ("DaVita" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is…
benzinga.com Barclays Maintains Equal-Weight on DaVita, Lowers Price Target to $216 Barclays analyst Andrew Mok maintains DaVita (NYSE:DVA) with a Equal-Weight and lowers the price target from $224 to $216.
benzinga.com TD Cowen Maintains Buy on DaVita, Raises Price Target to $228 TD Cowen analyst Ryan Langston maintains DaVita (NYSE:DVA) with a Buy and raises the price target from $220 to $228.
zacks.com DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/Y DVA's Q3 earnings surge 52.2% as revenues rise 4.6%, fueled by strong kidney care and international growth despite rising costs and margin pressure.
marketbeat.com What DaVita (DVA) Said on Its Q3 Earnings Call DaVita NYSE: DVA reported third-quarter adjusted operating income of $561 million, adjusted earnings per share of $3.82 and free cash flow of $276 million, while narrowing its full-year 2026 outlook.…
seekingalpha.com DaVita Inc. (DVA) Q3 2026 Earnings Call Transcript DaVita Inc. (DVA) Q3 2026 Earnings Call Transcript
zacks.com DaVita HealthCare (DVA) Beats Q3 Earnings and Revenue Estimates DaVita HealthCare (DVA) came out with quarterly earnings of $3.82 per share, beating the Zacks Consensus Estimate of $3.78 per share. This compares to earnings of $2.51 per share a year ago.
benzinga.com DaVita Q3 2026 Earnings Call Transcript DaVita (NYSE:DVA) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.
benzinga.com DaVita Q3 2026 Earnings Call Transcript DaVita (NYSE:DVA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com DaVita Q3 Adj. EPS $3.82 Beats $3.61 Estimate, Sales $3.578B Beat $3.508B Estimate DaVita (NYSE:DVA) reported quarterly earnings of $3.82 per share which beat the analyst consensus estimate of $3.61 by 5.82 percent. This is a 52.19 percent increase over earnings of $2.51 per share…
prnewswire.com DaVita Inc. 3rd Quarter 2026 Results DENVER, Oct. 29, 2026 /PRNewswire/ -- DaVita Inc. (NYSE: DVA) announced financial and operating results for the quarter ended September 30, 2026. Financial and operating highlights for the quarter…
prnewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. ("DaVita" or the "Company") (NYSE: DVA). Such investors are advised to contact…
globenewswire.com INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DaVita Inc. - DVA NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DaVita Inc. (“DaVita” or the “Company”) (NYSE: DVA). Such investors are advised to contact…
benzinga.com Health Care Stocks Hit Record Highs, GM Drops Nearly 8%: Stock Market Today Health care stocks climbed to record highs by midday Tuesday, with defensives and small caps leading a recovery from an early dip.
benzinga.com Michael Burry Warns Anthropic’s Valuation Could Buy 78 Profitable S&P 500 Companies: ‘Fun Game in Times Like These’ Michael Burry calls Anthropic's valuation a 'bubble,' noting it could buy 78 profitable S&P 500 companies like Domino's and Clorox.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Warren Buffett, Donald Trump Bet on Same 17 Stocks — Some Might Surprise You The investment portfolio of President Donald Trump and Berkshire Hathaway have 17 stocks in common. Here's a look at the list.
benzinga.com DaVita Reaches Preliminary Settlement Class Agreement Following Ransomware Attack A federal court preliminarily approves a class action settlement for 2.3 million patients affected by the DaVita ransomware attack.
benzinga.com Berkshire Hathaway Cut Capital One Stake by 58% in Q2 — Billionaire Dan Loeb Is Doing the Exact Opposite Berkshire slashed its Capital One stake by 58%, among its largest cuts, despite the stock's top growth score.- benzinga.com DaVita Enters Value-Based Care Agreement With Humana Medicare Advantage To Provide Care To Members With Chronic Kidney Disease Stages 3B–5 Launched July 1, this partnership builds on the organizations' long-standing collaboration in end stage kidney disease and expands earlier into the disease journey, when intervention can have the…
- benzinga.com TD Cowen Upgrades DaVita to Buy, Lowers Price Target to $220 TD Cowen analyst Ryan Langston upgrades DaVita (NYSE:DVA) from Hold to Buy and lowers the price target from $201 to $220.
benzinga.com The Economy Lost Jobs, Wall Street Threw a Party: What Moved Markets This Week US payrolls shrank by 23K in July. Here is how weak jobs data sparked gains for tech, gold, and top weekly movers.
benzinga.com Truist Securities Maintains Hold on DaVita, Lowers Price Target to $215 Truist Securities analyst David Macdonald maintains DaVita (NYSE:DVA) with a Hold and lowers the price target from $250 to $215.
benzinga.com Gold Jumps 4%, Dow Jones Smashes Record Highs: Stock Market Today Gold posts its biggest one-day gain since February and the Dow sets a record as Iran deal hopes cool inflation fears.
benzinga.com Toast To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Wednesday Wall Street analysts changed outlook on top names. UBS cut Fidelity National Information target, JP Morgan downgraded Ball, Needham raised Hinge Health.
benzinga.com SpaceX, Teradata, Pinterest And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures mixed, Dow up 100 points. SpaceX stock falls 10.3% after reporting strong Q2 revenue but a loss. Other stocks also decline.- benzinga.com Barclays Maintains Equal-Weight on DaVita, Raises Price Target to $224 Barclays analyst Andrew Mok maintains DaVita (NYSE:DVA) with a Equal-Weight and raises the price target from $218 to $224.
benzinga.com DaVita Q2 Adj. EPS $4.02 Beats $3.88 Estimate, Sales $3.554B Beat $3.496B Estimate DaVita (NYSE:DVA) reported quarterly earnings of $4.02 per share which beat the analyst consensus estimate of $3.88 by 3.61 percent. This is a 36.27 percent increase over earnings of $2.95 per share…- benzinga.com Truist Securities Maintains Hold on DaVita, Raises Price Target to $250 Truist Securities analyst David Macdonald maintains DaVita (NYSE:DVA) with a Hold and raises the price target from $205 to $250.
benzinga.com Barclays Maintains Equal-Weight on DaVita, Raises Price Target to $218 Barclays analyst Andrew Mok maintains DaVita (NYSE:DVA) with a Equal-Weight and raises the price target from $194 to $218.- benzinga.com 8 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com TD Cowen Maintains Hold on DaVita, Raises Price Target to $201 TD Cowen analyst Ryan Langston maintains DaVita (NYSE:DVA) with a Hold and raises the price target from $144 to $201.- benzinga.com Truist Securities Maintains Hold on DaVita, Raises Price Target to $205 Truist Securities analyst David Macdonald maintains DaVita (NYSE:DVA) with a Hold and raises the price target from $158 to $205.
- benzinga.com Barclays Maintains Equal-Weight on DaVita, Raises Price Target to $194 Barclays analyst Andrew Mok maintains DaVita (NYSE:DVA) with a Equal-Weight and raises the price target from $158 to $194.
benzinga.com S&P 500, Nasdaq 100 Smash Records As AMD Jumps 16% On AI Hype: Stock Market Today U.S. stocks hit records as Trump's Iran memo sinks oil 6%, AMD soars 17% on data-center beat.
benzinga.com This AMD Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday Top Wall Street analysts upgraded several top stocks. See all changes and ratings on Benzinga's analyst ratings page. Analysts are bullish on AMD.
benzinga.com Davita, Bloomin' Brands, Compass And Other Big Stocks Moving Higher On Wednesday Dow Jones up 500 points, DaVita Inc (DVA) shares rise after better-than-expected earnings and raised guidance. Other gaining stocks include EVC, BLMN, MNKD, FLEX, HUT, AVTX, COMP, VCYT, and SSRM.- benzinga.com Deutsche Bank Upgrades DaVita to Buy, Raises Price Target to $220 Deutsche Bank analyst Pito Chickering upgrades DaVita (NYSE:DVA) from Hold to Buy and raises the price target from $126 to $220.
benzinga.com DaVita Q1 Adj. EPS $2.87 Beats $2.32 Estimate, Sales $3.416B Beat $3.356B Estimate DaVita (NYSE:DVA) reported quarterly earnings of $2.87 per share which beat the analyst consensus estimate of $2.32 by 23.71 percent. This is a 43.5 percent increase over earnings of $2.00 per share…